Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To MOB-015 In EU
Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To MOB-015 In EU . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 STOCKHOLM, Dec. 10, 2024 /PRNewswire/ --  Moberg Pharma AB (OMX: MOB)   announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108978530/Moberg-Pharma-Reports-Topline-Data-In-The-North-American-Phase-3-Study-And-Will-Regain-Rights-To-MOB-015-In-EU
2024-12-10
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 STOCKHOLM, Dec. 10, 2024 /PRNewswire/ --  Moberg Pharma AB (OMX: MOB)   announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...
Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To MOB-015 In EU